Clinical trials: Chest--Diseases
Small Cell Lung Carcinoma
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
- Trial name
- NCT03319940
- Testing
- Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 269 people
- Sponsor
- Amgen
Keratosis
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
The purpose of this study is : To determine the maximum tolerated dose (MTD) for PEP005 Topical Gel in patients with actinic keratoses.
- Trial name
- NCT00239135
- Testing
- PEP005
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Peplin
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Non-small Cell Lung Cancer
Clinical Trial in Chinese Healthy Volunteers of GB222
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and…
- Trial name
- NCT04175158
- Testing
- GB222, Bevacizumab
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Non Small Cell Lung Cancer, Small-cell Lung Cancer
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side…
- Trial name
- NCT04022876
- Testing
- ALRN-6924, Carboplatin, Pemetrexed
- Where
- 28 sites in United States, Bosnia and Herzegovina and 5 more
- Volunteers
- 35 people
- Sponsor
- Aileron Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after…
- Trial name
- LUX-Lung-IO (NCT03157089)
- Testing
- Afatinib, pembrolizumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Lung Injury, Acute and Respiratory Distress Syndrome, Adult
Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery
Lung injury in patients undergoing oesophagectomy may occur during surgery (peri-operatively) as a result of One Lung Ventilation (OLV) and/or during the immediate post-operative period when patients receive intensive care.
- Trial name
- NCT02221037
- Testing
- GSK2862277
- Where
- 6 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern…
- Trial name
- NCT00085839
- Testing
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Where
- 19 sites in United States
- Volunteers
- 103 people
- Sponsor
- OSI Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the neoadjuvant therapy efficacy of IBI110 in combination with sintilimab versus sintilimab alone based on pathologic complete response (pCR) rate in stage IIB (primary tumor > 4 cm )…
- Trial name
- NCT05088967
- Testing
- IBI110, sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or…
- Trial name
- NCT01604863
- Testing
- HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Anemia
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
The primary objective of this study was to compare the effectiveness of darbopoetin alfa to placebo in the treatment of anemia in adults with lung cancer receiving multicycle platinum-containing chemotherapy, by assessing the…
- Trial name
- NCT03776032
- Testing
- Darbepoetin alfa
- Volunteers
- 320 people
- Sponsor
- Amgen
Locally Advanced Lung Cancer; Metastatic Lung Cancer
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in combination with standard platinum-based chemotherapy in participants with advanced NSCLC or SCLC.
- Trial name
- NCT03432598
- Testing
- Tislelizumab, Paclitaxel, Gemcitabine
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- BeiGene
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Colorectal Cancer, Esophageal Cancer
Clinical Trial Protocol for Evaluating the Efficacy and Safety of Thoracoabdominal Endoscopic Surgery System in Remote Laparoscopic Surgery for Urology, General Surgery, Gynecology and Thoracic Surgery
Evaluation of the Efficacy and Safety of the Thoracoabdominal Endoscopic Surgery System Produced by Shenzhen Cornerstone Robotics Technology Co., Ltd.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Hepatectomy, Radical Hysterectomy
- Trial name
- NCT07382635
- Testing
- Robot-assisted surgery
- Volunteers
- 98 people
- Sponsor
- Cornerstone Robotics
Recurrent Non Small Cell Lung Cancer
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients…
- Trial name
- TP2001-201 (NCT00652340)
- Testing
- apricoxib/erlotinib
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.
- Trial name
- NCT02388074
- Testing
- CyPath®
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- bioAffinity Technologies Inc.
Non Small Cell Lung Cancer
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
- Trial name
- NCT00434174
- Testing
- Everolimus, Pemetrexed
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Stable Angina, Unstable Angina
Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population
The aim of this study is to evaluate safety and efficacy performances of CRE8 Drug Eluting Stent, in patients comparable to the everyday's clinical practice population, with a specific focus on diabetics, that will be part of a…
- Conditions
- Stable Angina, Unstable Angina, Acute Myocardial Infarction
- Trial name
- PARTICIPATE (NCT01556126)
- Testing
- Amphilimus Eluting Stent (CRE8)
- Where
- 23 sites in Austria, Belgium and 4 more
- Volunteers
- 1,191 people
- Sponsor
- CID - Carbostent & Implantable Devices
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.